FTSE MIB
34.103,68 -47,73 (-0,14%) Dow Jones
39.056,39 +172,13 (+0,44%) Nasdaq
16.302,76 -29,80 (-0,18%) Nikkei 225
38.073,98 -128,39 (-0,34%) Petrolio
79,66 +0,67 (+0,85%) Bitcoin EUR
57.104,92 -883,67 (-1,52%)
AIM ImmunoTech Inc. (0A4Y.L)
- GlobeNewswire
AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
OCALA, Fla., Sept. 22, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAleer, Ph.D., Scientific Officer of AIM will present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., September 20-22, 2023. In addition to the presentation, the Company is proud to announce its sponsorship of the event. Details for the presentation are a
- GlobeNewswire
AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
Complete topline results confirm treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic) at 66%, comparable to pembrolizumab/neoadjuvant chemotherapy (NAC) Planned Phase 2 study in early-stage TNBC to determine if CKM including Ampligen may be a safe and effective alternative to pembrolizumab or in addition to pembrolizumab/NAC Results now available on ClinicalTrials.gov OCALA, Fla., Sept. 11, 2023 (GLOBE NEWS
- GlobeNewswire
AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference
OCALA, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY and virtually. In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registere
